I enjoy your posts, but for the love of G O D please don't compare me with Adam Feuerstein...I feel gross just thinking about that.
Everything else you said I concur, but man, trust me...I'm nothing like the #$%$ Bag AF.
You're right, CUR is still a tiny fish and is manipulated left and right.
I agree that the company is finally at a tipping point in which we will see some really nice gains...regardless of the bio indexes (which do need to settle down or pull back for about 3 consecutive weeks), but companies with some major catalysts like CUR should do very well.
BLRX --- by the way is a GREAT company. NVS owns 12%, recent institutional buying.
Plus on the back burner they have a drug that could treat people with Gluten Disease.
I love BLRX!
I can't believe how many conditions they have come up to treat with Brilacidin...pretty impressive...actually, very impressive.
Now if they continue to manage money as they have in the past without using ATM excessively, this will be in good shape.
100 Million Shares a day is NOT EVER going to happen, unless they actually Cure ALS.
All we need to show is that it is helping with ALS.
With all the conditions that CUR is planning on treating and they have POC in many already the market cap should be in the Billions.
Just think if CUR was going to put out their IPO this year when the bio's are on fire?
This would go over a Billion in a FLASH.
In an instant this would be well over a Billion Dollar company.
Why? IPO's are making National and even World wide news right now and CUR is basically Unknown still.
LOTS of Bashers on this Board and a Board without bashers indicates that the stock is worthless.
Bashers want cheap shares.
Some of them may even be dumb enough to short this.
Yes, that is what CUR has Needed to do, I mean it is time that more than two analysts know about and cover CUR. This should have about 9 analysts on this, just because this is such a small company, doesn't mean that they don't have dynamite products worth Billions.
Once they prove that this can treat Hippocampus disorders then the conditions to treat will be limitless.
Do some research on ALL the Hippocampal disorders....Google it.
That is why CUR will continue to Grow and Grow and there will be discovery after discovery. The best stem cells company is right HERE!
They really are LOADED and to me it's a no brainer on what to invest.
At the end of 2014 CUR was one of the companies voted to double in 2015. It already should be $6-$8 IMHO.
When only TWO analysts are familiar with CUR...CEO Garr isn't doing his job. At least he will be in front of people next week so the world can get to know CUR.
If he was smart he would double that, but I see that Aschoff's plate is full on a ton of other stocks. I think people are in shock of that one and don't really know all about the MOA's yet, so they are being very cautious, but once they find out just what it's doing they will find out they have a gold mine.
7. NSI-532- IGF: A new Treatment developed in Michigan for Alzheimer’s Disease. University of Michigan has Engineered Cortical Cells to Over-Express IGF-1. This will treat cognitive deficits in Alzheimer’s and this is still pre-clinical. They are still a Full Year away from finishing the Pre-Clinical #$%$ to move to Clinical Human Trials. Direct Quote from Dr. Eva Feldman after her team transplanted NSI-532-IGF stem cells in Animal model for Alzheimer’s disease “When you get something that works so beautifully (like this experiment), you can quickly see its translational potential. I am looking at a mouse, but someday I could be looking at a man. As a clinician scientist, those are the moments you live for.” Those are some powerful comments for a disease that needs options desperately in which there are no drugs to even halt the disease. Here is what Dr. Eva Feldman found out in Alzheimer’s studies with mice: "Those animals retained their ability to think, as a mouse does, to recognize objects so they looked just like an animal that doesn't have Alzheimer's disease," Feldman said. "It's really remarkable." NSI-532.IGF, consists of human cortex-derived neural stem cells that have been engineered to secrete human insulin-like growth factor 1 (IGF-1). In animal data presented at the Congress of Neurological Surgeons 2014 Annual Meeting, the cells rescued spatial learning and memory deficits in an animal model of Alzheimer's disease.
8. NSI-189 information about the Trial: The Drug had RAPID onset and Separation from the Placebo. A FULL publication of the Data is coming out later this year. ALL of the patients who took the drug had a clinical Meaningful Reduction in Depression. Some of the sections of the trial displayed Statistical Significance and they were NOT powered to show statistical significance. After the Following the patients after the administration of the drug up to day 84 in both trials there is NO Ebbing of the Effect… so CUR believes they are Structurally Re-building the Hippocampus. This drug was designed to be regenerative and have a neuroprotective effect on hippocampal neural stem cells. The Cognitive and Physical Functioning produced a very High P-Value with Statistical Significance. Once again…NO Ebbing of the effect through day 84….Folks this is UNHEARD OF! Rapid onset once again of the drug and it immediately separated from the Placebo group….which once again…wasn’t powered to demonstrate such Powerful / Incredible results. The Effect Remained STRONG after 80 Days, Way after the final dose…which is even more incredible. This is what influenced CUR to focus on Cognitive Deficit Schizophrenia. Now if they can find more….I’m sure they have the drug that will WORK! Folks…this is worth Billions….Am I the only one on this planet who recognizes this??? OK let’s talk about the D Effect …. Meaning the statistical design to show how strong the effect was no matter the size of the cohorts was off the chart folks. They also measured Alpha Wave increase which was Statistical Significant in INCREASING alpha waves…this drug is Re-Awakening the Brain. Other Biomarker data…such as blood work and saliva samples align with the effects of this drug, just another way of scientifically Validating this study. Then they measured the SDQ…this is the Combined Treatment Group P-Value---well this displayed Statistical Significance with a P-Value of .02. Validation!
9. NSI-566 – Cell Therapy for ALS. There have been 30 Patients and 36 Operations with Neural Stem Cell Injections completed so far. This was the world’s very First Spinal Injections. The injections were for Lumbar – Cervical -- or Both. There was NO Toxicity due to the injection of these Cells---Great News. There has been Definite Evidence of Long Term Cell Survival that was injected into the Gray Matter of the Spinal Cord. Bottom Line: Results will be positive because they are planning a Second Trial. CEO Garr Admits that some patients did NOT respond, so he asked the question: Why do some patients respond and others don’t? This will be a goal to find out in Phase II. The Groups that did best were the groups that received the most injections and the most cells…but this group was also the healthier group to begin with. They received 10 Lumbar injections and 5 Cervical injections. The Cervical injections are aimed at improving Breathing and Swallowing. The Lumbar injections are aimed at ambulatory factors and the major most important ones are Bowel and Bladder. Summary of Phase II: CUR dosed up to 400,000 cells per injection, 20 injections for each lumbar and cervical surgery. The first trial had a maximum of 100,00 cells per injection. They also significantly Increased the injections and they did this all with NO Toxicity…so are progressing Safely. They also learned that you CAN do up to at least 20 Spinal Injections without Compromising the integrity of the Spinal Cord. The cells HAVE provided Neurotrophic Support…meaning that they are helping, but evidently they are not having the same helpful effect on every patient and this is what CUR wants to discover WHY. AFTER the results are announced either in late February or early March they will be looking for Conferences to share their findings. UC San Diego is paying for the entire Spinal Cord Trial.
Ovarian Cancer is worth a LOT of $$$ and it's quick cash because treatments are few and far between and ineffective.
This should continue to move on up with accumulation.